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ABSTRACT
Pancreatic adenocarcinoma is currently the fourth leading cause for cancer-
related mortality. Malignant progression of pancreatic cancer depends not only on 
rapid proliferation of tumor cells but also on increased cell motility. In this study, we 
showed that increased PHLPP expression significantly reduced the rate of migration 
in pancreatic ductal adenocarcinoma (PDAC) cells whereas knockdown of PHLPP had 
the opposite effect. In addition, cell motility at the individual cell level was negatively 
regulated by PHLPP as determined using time-lapse imaging. Interestingly, the 
expression of β1 and β4 integrin proteins were decreased in PHLPP overexpressing 
cells and increased in PHLPP knockdown cells whereas the mRNA levels of integrin were 
not altered by changes in PHLPP expression. In determining the molecular mechanism 
underlying PHLPP-mediated regulation of integrin expression, we found that inhibition 
of lysosome activity rescued integrin expression in PHLPP overexpressing cells, thus 
suggesting that PHLPP negatively controls cell motility by inhibiting Akt activity to 
promote lysosome-dependent degradation of integrins. Functionally, the increased 
cell migration observed in PHLPP knockdown cells was effectively blocked by the 
neutralizing antibodies against β1 or β4 integrin. Taken together, our study identified 
a tumor suppressor role of PHLPP in suppressing cell motility by negatively regulating 
integrin expression in pancreatic cancer cells.
INTRODUCTION
Pancreatic adenocarcinoma is the fourth leading 
cause of cancer related deaths in the United States, 
despite being the ninth most diagnosed cancer in men 
and the eleventh in women. PDAC arises from the 
exocrine portion of the pancreas and accounts for 95% of 
all pancreatic adenocarcinoma [1]. PDAC has a dismal 
5-year survival rate of 4% and a median survival span of 
6 months from the point of diagnosis, and it has a high 
rate of chemotherapy and radiation resistance [1]. Thus, 
a better understanding of the molecular events leading 
to cancer progression is needed in order to improve the 
treatment and prognosis of PDAC patients.
Accumulation of genetic mutations in oncogenes and 
tumor suppressors lead to the development of pre-malignant 
lesions which eventually through genetic instability give rise 
to carcinoma within the pancreatic ductal epithelium [2]. 
Key mutations in oncogenes such as KRAS with deactivation 
of tumor suppressor genes SMAD4 and CDKN2A/INK4A 
have been implicated in the development and progression 
of pancreatic cancer [3, 4]. In addition, it has been shown 
that overexpression of integrin α6β4 promotes migration 
and invasion of pancreatic cancer cells and is associated 
with the progression of PDAC [5, 6]. Integrins are known 
to contribute to tumor progression and metastasis by directly 
activating a number of oncogenic signaling pathways, 
including PI3K/Akt and RAS/RAF pathways, in various 
types of cancer [7, 8]. However, the molecular mechanism by 
which the expression of integrin proteins is regulated remains 
elusive in pancreatic cancer cells.
PHLPP (PH domain leucine-rich repeat protein 
phosphatase) belongs to a novel family of Ser/Thr protein 
phosphatases. There are two isoforms, PHLPP1 and 
PHLPP2, identified in this family [9–12]. Both PHLPP 
isoforms were first discovered as the phosphatases for 
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Akt that directly dephosphorylate the hydrophobic motif 
Ser473 site and inactivate the kinase [9, 10]. Moreover, it 
has been shown that PHLPP dephosphorylates Ser338, a 
key activation site on RAF1, and inhibits the downstream 
signaling through RAF/MEK/ERK in colon cancer cells 
[13]. Therefore, PHLPP may exert its tumor suppressor 
function by negatively regulating both the PI3K/Akt and 
RAS/RAF pathways. Recently, Nitsche et al discovered 
that there is a stage-dependent downregulation of PHLPP 
in pancreatic cancer patient specimens, thus suggesting a 
tumor suppressor role of PHLPP in pancreatic cancer [14]. 
However, it remains unknown whether loss of PHLPP 
expression promotes cancer cell migration in pancreatic 
cancer.
In this study, we determined the role of PHLPP 
in regulating cell migration and motility in pancreatic 
cancer cells. We identified a functional connection 
between PHLPP expression and integrin function. 
Results from our study revealed that PHLPP-loss 
increases cell motility by upregulating integrin 
expression and inducing EMT. Furthermore, we found 
that PHLPP negatively controls integrin expression by 
promoting lysosome-mediated degradation of integrin 
via inhibition of Akt.
RESULTS
PHLPP negatively regulates the activity of Akt 
and MEK/ERK in pancreatic cells
To determine if PHLPP serves as a tumor 
suppressor in human pancreatic cancer, we established 
stable cell lines overexpressing PHLPP1 or PHLPP2 
in Panc-1 cells, which express very low levels of 
endogenous PHLPPs. The PHLPP1 gene potentially 
encodes two differentially spliced variants, PHLPP1α 
and PHLPP1β [11]. Since the longer transcript of 
PHLPP1, PHLPP1β, is the predominant form expressed 
endogenously in all pancreatic cell lines examined, we 
used PHLPP1β in our study. We first determined the 
effect of PHLPP overexpression on cell signaling. As 
shown in Figure 1, both Akt and MEK/ERK activity 
were downregulated in PHLPP overexpressing cells 
compared to control cells as indicated by decreased 
Figure 1: Overexpression of PHLPP isoforms inhibit PI3K/Akt and MEK/ERK signaling. A. Stable control, HA-PHLPP1β 
or HA-PHLPP2 overexpressing Panc-1 cells were generated using retrovirus-mediated infection. The cell lysates were prepared and 
analyzed for phosphorylation and total protein expression by immunoblotting. B. Relative phosphorylation for p-Akt, p-MEK, p-ERK 
were calculated and normalized to those of total Akt, MEK and ERK, respectively. The level in control cells was set to 1. Data represent the 
mean ± SEM (n = 3, * p<0.05 by two-sample t-tests).
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phosphorylation of Akt, MEK, and ERK. Next, to 
determine the effect of endogenous PHLPP on Akt 
and MEK/ERK signaling, PHLPP was silenced in 
ASPC-1 cells, which express relatively higher levels of 
endogenous PHLPPs, using lentiviral-mediated RNAi. 
Immunoblotting results revealed that phosphorylation 
of Akt, MEK, and ERK was significantly elevated 
when PHLPP expression was knocked down 
(Figure 2). Consistent with previous reports on the 
tumor suppressor function of PHLPP in other cancer 
types [13, 15–18], our results here provide the initial 
evidence that PHLPP is capable of inhibiting both Akt 
and MEK/ERK signaling in pancreatic cancer cells.
PHLPP negatively regulates cell migration in 
pancreatic cancer cells
Previous studies of PHLPP expression in 
colorectal cancer cells showed an enhanced ability 
for PHLPP knockdown cells to migrate and transition 
into EMT [13]. To test if PHLPP regulates cell motility 
in pancreatic cancer cells, we first examined the 
expression of EMT markers in PHLPP overexpressing 
Panc-1 and PHLPP knockdown ASPC-1 cells. As 
shown in Figure 3A, PHLPP overexpression markedly 
increased the expression of E-cadherin, an epithelial 
cell marker, and decreased the expression of vimentin, 
a mesenchymal cell marker. Conversely, knockdown 
of either PHLPP isoform decreased E-cadherin 
whereas increased vimentin expression (Figure 3A), 
suggesting that PHLPP downregualtion promotes EMT 
in pancreatic cancer cells. Furthermore, we found that 
PHLPP overexpressing cells migrated significantly 
slower than the control cells as determined by 
Transwell migration assays (Figure 3B). In contrast, 
knockdown of PHLPP significantly enhanced the 
ability of pancreatic cancer cells to migrate in response 
to HGF. Similar results were obtained when using 
IGF-1 and collagen were used as chemoattractants 
(Supplementary Figure S1).
We next determined the effect of PHLPP on 
modulating cell motility at the single cell level. To 
this end, PHLPP overexpressing Panc-1 and PHLPP 
knockdown ASPC-1 cells were subjected to cell 
Figure 2: Loss of PHLPP expression enhances PI3K/Akt and MEK/ERK signaling. A. Stable control (sh-Con) and PHLPP 
knockdown (sh-PHLPP1 and sh-PHLPP2) ASPC-1 cells were generated using lentivirus-mediated RNAi. The cell lysates were analyzed for 
phosphorylation and total protein expression by immunoblotting. B. Relative phosphorylation for p-Akt, p-MEK, p-ERK were calculated 
and normalized to those of total Akt, MEK and ERK, respectively. The level in control cells was set to 1. Data represent the mean ± SEM 
(n = 3, * p<0.05 by two-sample t-tests).
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tracking experiments to monitor the cell movement 
in real time. We found that overexpression of PHLPP 
resulted in a significant decrease in cell motility when 
compared to the control cells (Figure 4A), whereas 
PHLPP knockdown cells were considerably more 
motile (Figure 4D). The velocity and average distances 
traveled were significantly decreased in PHLPP 
overexpressing cells (Figure 4B–4C) while significantly 
increased in PHLPP knockdown cells (Figure 4E–4F). 
Taken together, we have identified a role of PHLPP 
in inhibiting EMT and cell motility in pancreatic 
cancer cells.
Figure 3: Knockdown of PHLPP expression induces EMT and promotes cell migration. A. Cell lysates were prepared from 
stable control and PHLPP overexpressing Panc-1 as well as PHLPP knockdown ASPC-1 cells. The expression levels of E-cadherin and 
vimentin were analyzed using immunoblotting. B. Stable control and PHLPP overexpressing Panc-1 cells were subjected to Transwell 
migration assays using HGF and laminin as chemoattractants. C. Stable control and PHLPP knockdown ASPC-1 cells were subjected to 
Transwell migration assays using HGF and laminin as chemoattractants. The inserts shown in (B) and (C) were representative images of 
cells migrated in the Transwell assays. Each experiment was done in duplicates and three independent experiments were averaged and 
expressed as mean ± SEM (* p<0.05 by two-sample t-tests compared to the control cells).
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Figure 4: PHLPP controls cell motility at the single cell level. A. Migration patterns of stable control and PHLPP overexpressing 
Panc-1 cells on laminin coated plates using HGF as the chemoattractant. The trajectories of 12 randomly chosen cells for each cell line were 
plotted in the graphs. B–C. The average distance traveled (B) and the relative velocity (C) of 12 stable control and PHLPP overexpressing 
Panc-1 cells during 6 hours of migration. Data represent mean ± SD (n = 12 cells/line, * p<0.05 by two-sample t-tests). D. Migration 
patterns of stable control and PHLPP knockdown ASPC-1 cells on laminin coated plates using HGF as the chemoattractant. The trajectories 
of 12 randomly chosen cells for each cell line were plotted in the graphs. E–F. The average distance traveled (E) and the relative velocity 
(F) of 12 stable control and PHLPP knockdown ASPC-1 cells during 6 hours of migration are shown. Data represent mean ± SEM (n = 12 
cells/line, * p<0.05 by two-sample t-tests).
Oncotarget7806www.impactjournals.com/oncotarget
PHLPP inhibits the invasive growth of 
pancreatic cancer cells in 3D culture
To further determine the effect of PHLPP on invasive 
growth of pancreatic cancer cells, we used 3D cell culture 
systems as they closely mimic the cancer microenvironment 
and they provide a better opportunity to explore the effects 
of oncogenes and tumor suppressors on modulating 
morphogenesis as well as invasive growth [19, 20]. Both 
PHLPP overexpressing Panc-1 and PHLPP knockdown 
ASPC-1 cells were seeded into Matrigel and allowed to 
grow for up to 7 days. The control Panc-1 cells grew into 
large multi-globular clusters with spikes of membrane 
protrusions extending into Matrigel (Figure 5A–5B). 
However, the formation of membrane protrusions was 
completed blocked in PHLPP overexpressing cells and the 
size of cell clusters was significantly decreased (Figure 5C). 
In addition, TIRF images of control Panc-1 cells showed 
the formation of both stress fibers and long filamentous 
extensions at the basolateral membrane surrounding 
the entire cell whereas very few actin stress fibers were 
observed in PHLPP overexpressing cells (Supplementary 
Figure S2). Although no clear membrane protrusions were 
observed in ASPC-1 cells grown in Matrigel, PHLPP 
knockdown cells formed significantly larger globular 
clusters compared to the control cells, suggesting that 
PHLPP-loss increases the invasive growth ability of 
pancreatic cancer cells (Figure 6A–6C).
Figure 5: PHLPP inhibits the invasive phenotype of pancreatic cancer cells grown in 3D culture. A–B. Stable control and 
PHLPP overexpressing Panc-1 cells were seeded in Matrigel and allowed to grow for 7 days. On the 3rd day (A) and the 7th day (B) after 
seeding phase-contrast images were taken with the 10X objective on using an inverted Nikon microscope. The boxed regions were enlarged 
and shown next to the original images. Scale bars, 100 μm. C. The size of cell clusters at day 7 was measured and analyzed using Nikon 
Element AR software. Data represent mean ± SEM (n = 18 cells/line, * p<0.05 by two-sample t-tests).
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PHLPP regulates the expression of integrin in 
pancreatic cancer cells
Previous studies have shown that increased β4 
integrin expression is associated with pancreatic cancer 
progression [5]. Interestingly, when examining the 
expression of β integrin, we found that expression of 
both β4 and β1 integrin were significantly reduced in 
PHLPP overexpressing Panc-1 cells and increased in 
the PHLPP knockdown ASPC-1 cells (Figure 7A–7C). 
To further determine if PHLPP-mediated regulation 
of β4 and β1 integrin expression is controlled at the 
transcriptional level, total RNAs were isolated from 
PHLPP overexpressing Panc-1 and PHLPP knockdown 
Figure 6: Knockdown of PHLPP promotes the invasive growth of pancreatic cancer cells in 3D culture. A–B. Stable 
control and PHLPP knockdown ASPC-1 cells were seeded in Matrigel and allowed to grow for 7 days. On the 5th day (A) and the 7th 
day (B) after seeding phase-contrast images were taken with the 10X objective on using an inverted Nikon microscope. Scale bars, 100 
μm. C. The size of cell clusters at day 7 was measured and analyzed using Nikon Element AR software. Data represent mean ± SEM 
(n = 18 cells/line, * p<0.05 by two-sample t-tests).
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Figure 7: PHLPP regulates integrin protein expression. A. Cell lysates prepared from PHLPP overexpressing Panc-1 and PHLPP 
knockdown ASPC-1 cells were analyzed for the expression of β1 and β4 integrin and tubulin using immunoblotting. B–C. Relative 
expression of β1 (B) and β4 integrin (C) was calculated and normalized to tubulin. The level in control cells was set to 1. Data represent the 
mean ± SEM (n = 3, * p<0.05 by two-sample t-tests). D–E. Total RNAs were isolated from PHLPP overexpressing Panc-1 cells (D) and 
PHLPP knockdown ASPC-1 cells (E). Real-time PCR analysis was performed using probes specific for human β1 and β4 integrin genes. 
Each experimental point was done in triplicates, and the graphs represent the mean ± SD (n = 3).
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ASPC-1 cells, and real-time PCR (RT-PCR) analysis was 
performed using probes specific for the β4 or β1 integrin 
gene. The results revealed that the mRNA levels of β4 
and β1 integrin were not decreased by changes in PHLPP 
expression (Figure 7D–7E). Interestingly, the levels of 
β4 and β1 integrin mRNA were increased in PHLPP1β 
overexpressing cells. However, since the expression of 
β4 and β1 integrin proteins was decreased in PHLPP1β 
overexpressing cells, this increase of integrin mRNA was 
unlikely the reason for PHLPP-mediated downregulation 
of integrin. Collectively, these results indicated that 
PHLPP negatively regulates integrin expression via a post-
translational mechanism in pancreatic cancer cells.
To further investigate the mechanism by which 
PHLPP regulates integrin expression, we tested if the 
PI3K/Akt or the MEK/ERK pathway is involved in 
controlling the expression of integrin proteins. Inhibiting 
the PI3K/Akt pathway using a PI3K inhibitor, LY294002, 
in ASPC-1 cells resulted in an approximately 40% 
reduction in both β4 and β1 integrin expression over time 
(Figure 8A–8B). A similar decrease of integrin expression 
was seen in cells treated with an Akt inhibitor, Akt-VIII 
(Supplementary Figure S3). However, treating cells with a 
MEK inhibitor, PD325901, had no effect on the expression 
of integrin (Supplementary Figure S3), suggesting that 
PHLPP-induced downregulation of integrin is likely 
mediated through inhibition of Akt signaling. As a 
control, we found that the mRNA levels of integrin were 
not significantly changed in cells treated with LY294002 
(Supplementary Figure S3).
Recent studies have suggested that integrins can 
be internalized upon binding to extracellular matrix 
(ECM) ligands and trafficked to lysosome for degradation 
[21–24]. To determine if decreased integrin expression 
seen in PHLPP overexpressing cells is due to increased 
lysosomal degradation, we incubated control and PHLPP 
overexpressing Panc-1 cells in NH4Cl containing media. 
The presence of NH4Cl, a lysosomotropic alkalinizing 
agent, inhibits lysosomal protein degradation. At the end 
of 8-hour treatment with NH4Cl, both β4 and β1 integrin 
expression increased in response to lysosome inhibition 
and the expression of integrin in PHLPP overexpressing 
cells was similar to that of the control cells (Figure 8C). 
Similar results were obtained in cells treated with a 
different lysosome inhibitor, chloroquine (Supplementary 
Figure S3). In addition, we determined if PHLPP promotes 
integrin ubiquitination since ubiquitination has been linked 
to lysosome-mediated degradation of integrin [21, 24]. 
Endogenous β4 and β1 integrin were immunoprecipitated 
from control and PHLPP overexpressing Panc-1 cells, 
and the ubiquitination levels of β4 and β1 integrin were 
increased in both PHLPP1β and PHLPP2 overexpressing 
cells (Figure 8D). Furthermore, since it has been shown 
that activation of PI3K/Akt signaling promotes integrin 
recycling to the plasma membrane by inhibiting GSK-3β 
[25], we examined if PHLPP-mediated downregulation 
of integrin can be rescued by inhibiting GSK-3 activity 
directly. Indeed, when treating cells with LiCl, a 
GSK-3 inhibitor, the expression of β1 and β4 integrin 
increased in both control and PHLPP overexpressing 
cells (Supplementary Figure S4). Taken together, our 
results suggest that PHLPP may downregulate β4 and 
β1 integrin expression by increasing the ubiquitination 
of these proteins, and inhibition of lysosome-mediated 
protein degradation rescues integrin expression in PHLPP 
overexpressing cells.
Blocking integrin activity inhibits PHLPP-loss 
induced increase in cell motility
To determine the functional impact of PHLPP-
mediated inhibition of integrin expression, we examined 
the rate of cell migration in control and PHLPP 
knockdown ASPC-1 cells in the presence of blocking 
antibodies against β4 or β1 integrin. As shown in Figure 
9A, incubating cells with either β4 or β1 integrin blocking 
antibodies significantly reduced cell migration in both 
control and PHLPP knockdown cells as measured by 
Transwell assays. Moreover, inhibiting integrin activation 
impaired cell motility at the single cell level as the 
relative velocity in the control and PHLPP knockdown 
cells became indistinguishable after the blocking antibody 
treatment (Figure 9B). These data suggested that increased 
integrin expression in PHLPP knockdown cells is 
responsible for increased cell migration.
DISCUSSION
A number of recent studies have provided strong 
evidence suggesting that PHLPP serves as an important 
tumor suppressor in various cancer types [9, 10, 12, 15–
17, 26]. For example, it has been shown that PHLPP is 
downregulated in colon cancer patients and decreased 
PHLPP expression promotes tumor growth as the result 
of increased activation of both PI3K/Akt and RAS/
RAF oncogenic signaling [12, 13, 15]. However, the 
role of PHLPP in regulating cell migration has not 
been determined in pancreatic cancer. Here we show 
that PHLPP plays an important role in controlling cell 
motility. Specifically, overexpression of either PHLPP 
isoform decreases cell migration whereas knockdown of 
endogenous PHLPPs significantly enhances cell motility 
in pancreatic cancer cells. Moreover, the level of PHLPP 
expression negatively regulates the ability of pancreatic 
cancer cells to grow in 3D culture. This PHLPP-mediated 
inhibition of cell growth and migration is coincided 
with inhibition of both Akt and MEK/ERK activation. 
Mechanistically, PHLPP inhibits β1 and β4 integrin 
expression by increasing ubiquitination and lysosome-
mediated degradation of integrin proteins, and blocking 
integrin activation reverses PHLPP-loss induced increase 
in cell migration. Consistent with a previously published 
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Figure 8: Inhibition of PI3K/Akt pathway promotes lysosome-mediated integrin degradation. A. ASPC-1 cells were 
incubated with LY294002 for 0–12 hours. At indicated time points, cell lysates were prepared and analyzed for the expression of β1 and β4 
integrin and tubulin using immunoblotting. B. Relative expression levels of β1 and β4 integrin at different time points following LY294002 
treatment in ASPC-1 cells were calculated and normalized to tubulin. The level in untreated cells was set to 1. Data represent the mean 
± SEM (n = 3, * p<0.05 by two-sample t-tests). C. Stable control and PHLPP overexpressing Panc-1 cells were treated with NH4Cl (5 
mM) for 2, 4, and 8 hours. Cell lysates were prepared and analyzed by immunoblotting for integrin expression. D. Cell lysates prepared 
from stable control and PHLPP overexpressing Panc-1 cells were immunoprecipitated with antibodies against β1 or β4 integrin. The 
ubiquitination of endogenous β1 and β4 integrin was detected using the anti-ubiquitin antibody.
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study [14], we find that overexpression of PHLPP isoforms 
promote cell death but have little effect on proliferation in 
PDAC cells (data not shown). Taken together, our findings 
establish a novel link connecting PHLPP downregulation 
with enhanced integrin function in pancreatic cancer.
The cell surface delivery and endocytosis of 
integrins are dynamically regulated processes and 
fundamental for cell migration in wound healing and 
during cancer cell metastasis [27, 28]. Like many cell 
surface receptors, integrins are known to undergo 
endo/exocytic cycles, in which they are internalized, 
trafficked through endosome, and then recycled back 
to the plasma membrane [7, 28–30]. This recycle 
process occurs rather efficiently as the degradation 
rates of integrins are generally very slow [24, 31], 
however, ligand-bound integrins can be ubiquitinated 
Figure 9: The PHLPP-mediated regulation of cell migration relies on its ability to control integrin expression. A. Stable 
control and PHLPP knockdown ASPC-1 cells were subjected to Transwell migration analysis using HGF as the chemoattractant. To block 
integrin activation, ASPC-1 cell suspensions were incubated with blocking antibodies of β1 or β4 integrin in serum-free media containing 
1% BSA for 20 minutes at 4 °C. The cells were then seeded onto the collagen coated Transwells in the presence of the blocking antibodies 
and allowed to migrate for 4 hours at 37°C. Each experiment was done in duplicates and three independent experiments were averaged and 
expressed as mean ± SEM (* p<0.01 by two-sample t-tests compared to the control cells). B. Cells as treated as above with blocking antibodies 
were monitored for single cell motility using time-lapse imaging. The cells were allowed to migrate in response to HGF for 6 hours. The 
average velocities of 12 cells from each group are shown. Data represent mean ± SEM (n = 12 cells/line, * p<0.05 by two-sample t-tests).
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and sorted to lysosome for degradation by the ESCRT 
pathway [24, 32]. Our findings that overexpression of 
PHLPP reduces the expression of β1 and β4 integrin 
and enhances their ubiquitination suggest that PHLPP 
may negatively control cell motility by inhibiting Akt 
activity to promote lysosome-dependent degradation 
of integrin. Since preventing lysosome-mediated 
degradation of integrins increases recycling of integrins 
to the plasma membrane and enhances integrin-
mediated cancer cell migration and invasion [29, 30], 
PHLPP represents a novel regulator of cell motility 
by controlling the balance of integrin recycling and 
degradation in pancreatic cancer cells.
Previous studies have shown that the protein 
expression of both PHLPP isoforms are reduced in 
pancreatic cancer patient specimens compared to normal 
pancreases tissues [14]. We have interrogated the mRNA 
expression of PHLPP in several gene expression databases 
and found that the expression of PHLPP1 is significantly 
decreased in pancreatic tumor samples compared to normal 
samples whereas PHLPP2 mRNA expression is less 
affected (Supplementary Figure S5). Thus, loss of PHLPP 
protein expression in pancreatic cancer is likely mediated 
via a post-transcriptional or post-translational mechanism. 
Interestingly, recent studies have identified PHLPP2 as a 
bona fide target for a number of oncogenicmicroRNAs 
(miRNAs), including miR-372, miR-224 and miR-17~92, 
in difference cancer types [33–35]. In addition, single 
nucleotide variations in both PHLPP genes are rare (<1% 
based on COSMIC collections of somatic mutations). 
Future studies are needed to determine the mechanism 
leading to downregulation of PHLPP proteins.
Due to the late stage diagnosis and the aggressive 
nature of the carcinoma itself, PDAC patients have a very 
low survival rate [1, 4]. The treatment options for PDAC 
are few and surgical resection is nearly impossible for 
the average patient [36]. Understanding the molecular 
mechanism leading to EMT and progression of PDAC 
potentially has a long lasting benefit in creating 
new treatment strategies. In this study, we provide 
strong evidence supporting a tumor suppressor role 
of PHLPP in pancreatic cancer. Moreover, our finding 
that decreased PHLPP expression promotes EMT and 
cell motility through inhibiting lysosome degradation 
of integrin proteins identifies a novel mechanism by 
which PHLPP suppresses oncogenic signaling. Recent 
studies have demonstrated that upregulation of β4 
integrin is associated with the EMT phenotype and poor 
prognosis in pancreatic cancer [37] and increased β1 
integrin expression in tamoxifen-resistant breast cancer 
cells promotes EMT [38]. Future studies are needed 
to determine if PHLPP-loss induced EMT requires 
upregulation of integrin in PDAC cells. Collectively, 
our study highlights the importance of further exploring 
PHLPP as a possible diagnostic marker for targeted 
therapy in pancreatic cancer.
EXPERIMENTAL PROCEDURES
Cells and reagents
The following pancreatic ductal adenocarcinoma 
cell lines, including ASPC-1, Panc-1, and Suit-2, were 
kindly provided by Dr. Kathleen O’Connor (University 
of Kentucky). The Panc-1 cells used in this study were 
sorted for their high integrin expression as described 
previously [6]. Panc-1 cells were cultured in DMEM 
whereas ASPC-1 cells were cultured in RPMI-1640. All 
media were supplemented with 10% fetal bovine serum 
(FBS, Sigma-Aldrich) and 1% penicillin/streptomycin. 
The shRNAs used to knockdown human PHLPP1 or 
PHLPP2 gene and the retroviral expression plasmids, 
including pBabe-puro-HA-PHLPP1β and pBabe-
puro-HA-PHLPP2, have been described previously 
[13, 15]. The stable PHLPP overexpressing cells were 
generated by infecting cells with retrovirus encoding 
HA-PHLPP1β or HA-PHLPP2 and selecting with 
puromycin (1 μg/ml).
The PHLPP1 and PHLPP2 antibodies were 
obtained from Proteintech and Bethyl Laboratories, 
respectively. The phospho-Akt (p-Akt for the Ser473 
site), phospho-ERK1/2 (p-ERK for Thr202/Tyr204), 
phospho-MEK1/2 (p-MEK for Ser217/221), and 
E-cadherin antibodies were from Cell Signaling. The 
vimentin antibody was from BD Biosciences, the g 
tubulin antibody was from Sigma-Aldrich, and the 
ubiquitin antibody was from Santa Cruz Biotechnology. 
The following integrin antibodies were used in this 
study: for Western blotting, anti-β1 rabbit mAb (D2E5, 
Cell Signaling) and anti-β4 mouse mAb (clone 7, BD 
Biosciences); and for blocking ECM binding and 
immunoprecipitation, anti-β1 mouse mAb (clone 
6S6, Millipore) and anti-β4 mouse mAb (clone ASC-
8, Millipore). The following chemicals, including 
PI3K inhibitor LY290042 and Akt inhibitor VIII, were 
purchased from EMD/CalBiochem. The MEK1/2 
inhibitor PD0325901 was purchased from Selleck 
Chemicals, and lysosome inhibitor chloroquine was from 
Sigma-Aldrich.
Immunoblotting
Cultured cells were harvested and lysed in Lysis 
Buffer (50 mM Na2HPO4, 1 mM sodium pyrophosphate, 
20 mM NaF, 2 mM EDTA, 2 mM EGTA, 1% Triton 
X-100, 1 mM DTT, 200 mM benzamidine, 40 mg ml-1 
leupeptin, 200 mM PMSF) and the detergent-solublized 
cell lysates were obtained after centrifugation for 5 
minutes at 16,000 g at 4 oC. Equal amounts of cell lysates 
as determined by Bradford assays were resolved by SDS-
PAGE and subjected to immunoblotting analysis. The 
density of ECL signals was obtained and quantified using 
a FluoChem digital imaging system (Alpha Innotech).
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Transwell migration assays
Serum starved pancreatic cancer cells were seeded 
into the upper chamber of Transwell inserts with an 8-mm 
pore size membrane (Corning). For migration assays, the 
bottom of the inserts were coated with collagen (15 mg/
ml) or laminin (25 μg/ml), and the cells were allowed to 
migrate towards media containing either HGF (20 ng/ml) 
or IGF (20 ng/ml) in the lower chamber for 2-5 hours. At 
the end of the incubation period, Transwell inserts were 
fixed in methanol and stained with 0.5% crystal violet. 
The numbers of cells that were migrated to the lower 
chamber of the Transwell were counted using an inverted 
microscope at 20X magnification.
Time-lapse live cell imaging and analysis
Stable control and PHLPP overexpressing Panc-1 
cells and PHLPP knockdown ASPC-1 cells were serum 
starved for 2 hours and seeded as single cells onto collagen 
(15 mg/ml) or laminin (25 mg/ml) coated glass bottom 
culture dishes (MatTek). The migration of live cells was 
recorded in media containing HGF (20 ng/ml) using Nikon 
BioStation IM equipped with CO2 incubation chamber. 
Time-lapse phase images were taken either every 5 or 10 
minutes for 6 hours with a 20X objective. The movement 
of cells was tracked and analyzed using Nikon Element 
AR software.
3D cell culture
Single cell suspension of pancreatic cancer cells was 
prepared in serum free media and embedded into collagen/
Matrigel (1:1) mixture. The cells were overlaid with 2% 
Matrigel in 2% FBS containing media. The cells were 
allowed to grow into cyst-like structures in the 3D matrix 
for 1-2 weeks. The size and morphology of the cysts were 
examined by phase-contrast microscopy using a Nikon 
Ti-E inverted microscope. For immunofluorescence 
staining, the cysts were fixed in 4% paraformaldehyde 
and permeabilized using 1% Triton X-100 in PBS. Actin 
was stained using Alexa 488-conjugated phalloidin while 
the nuclei of the cells were stained with DAPI-containing 
mounting medium. Cells were visualized using an 
Olympus FlowView FV1000 confocal laser-scanning 
microscope.
Real-time PCR
Total RNA was isolated with RNeasy kit (Qiagen) 
from different stable pancreatic cancer cell lines. 
Equal amounts of RNA were used as templates for the 
synthesis of cDNA using High Capacity cDNA Reverse 
Transcription kit (Applied Biosysems). Real-time PCR 
reaction was performed using the StepOne Real-Time 
PCR system (Applied Biosysems) with β1- and β4-specific 
probes. All values were normalized to the level of β-actin.
Statistical analysis
Normalized microarray and patient clinical 
data from two pancreatic cancer studies [39, 40] were 
downloaded from the Oncomine database. The Badea et 
al data [40] contain matched tumor and normal samples 
from 36 pancreatic cancer patients. The TCGA data [39] 
contain tumor samples from 65 pancreatic cancer patients 
and normal samples from 65 patients, within which 64 
patients have both tumor and normal samples. Expression 
levels of multiple probes mapping to the same gene were 
averaged. Gene expressions from replicated tumor or 
normal samples for the same patient were also averaged. 
The paired t-test or linear mixed model was used to 
compare PHLPP1 and PHLPP2 expressions between 
tumor and normal samples.
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